This paper is in the following e-collection/theme issue:

Electronic/Mobile Data Capture, Internet-based Survey & Research Methodology (788) Medicine 2.0: Social Media, Open, Participatory, Collaborative Medicine (1570) Neurology and Neurosciences (149)

Published on in Vol 20, No 10 (2018): October

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/11168, first published .
The Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study

The Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study

The Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study

Authors of this article:

Kristina F Simacek1 Author Orcid Image ;   John J Ko2 Author Orcid Image ;   Debbie Moreton3 Author Orcid Image ;   Stefan Varga4 Author Orcid Image ;   Kristen Johnson2 Author Orcid Image ;   Bozena J Katic1 Author Orcid Image
Article Authors Cited by (31) Tweetations (10) Metrics

Journals

  1. Boyden A, Brate A, Stephens L, Karandikar N. Immune Autoregulatory CD8 T Cells Require IFN-γ Responsiveness to Optimally Suppress Central Nervous System Autoimmunity. The Journal of Immunology 2020;205(2):359 View
  2. Zuckerman A, Carver A, Cooper K, Markley B, Mitchell A, Reynolds V, Saknini M, Wyatt H, Kelley T. An Integrated Health-System Specialty Pharmacy Model for Coordinating Transitions of Care: Specialty Medication Challenges and Specialty Pharmacist Opportunities. Pharmacy 2019;7(4):163 View
  3. Hartung D, Johnston K, Geddes J, Bourdette D. Effect of generic glatiramer acetate on spending and use of drugs for multiple sclerosis. Neurology 2020;94(13) View
  4. Ashkenazy N, Saboo U, Robertson Z, Cao J. The effect of patient compliance on remission rates in pediatric noninfectious uveitis. Journal of American Association for Pediatric Ophthalmology and Strabismus 2019;23(6):334.e1 View
  5. Vališ M, Šarláková J, Halúsková S, Klímová B, Potužník P, Peterka M, Kuča K, Štourač P, Mareš J, Pavelek Z. An observational study demonstrating the adherence and ease of use of the injector device, RebiSmart®. Expert Opinion on Drug Delivery 2020;17(5):719 View
  6. Hartung D, Alley L, Johnston K, Bourdette D. Qualitative study on the price of drugs for multiple sclerosis. Neurology 2020;94(4) View
  7. Carnero Contentti E, Giachello S, Correale J. Barriers to access and utilization of multiple sclerosis care services in a large cohort of Latin American patients. Multiple Sclerosis Journal 2021;27(1):117 View
  8. Grundstrom C, Korhonen O, Väyrynen K, Isomursu M. Insurance Customers’ Expectations for Sharing Health Data: Qualitative Survey Study. JMIR Medical Informatics 2020;8(3):e16102 View
  9. Matthews P, Block V, Leocani L. E-health and multiple sclerosis. Current Opinion in Neurology 2020;33(3):271 View
  10. Zhang Y, Salter A, Jin S, Culpepper W, Cutter G, Wallin M, Stuve O. Disease-modifying therapy prescription patterns in people with multiple sclerosis by age. Therapeutic Advances in Neurological Disorders 2021;14:175628642110064 View
  11. Moisset X, Fouchard A, Pereira B, Taithe F, Mathey G, Edan G, Ciron J, Brochet B, De Sèze J, Papeix C, Vermersch P, Labauge P, Defer G, Lebrun‐Frenay C, Moreau T, Laplaud D, Berger E, Pelletier J, Stankoff B, Gout O, Thouvenot E, Heinzlef O, Al‐Khedr A, Bourre B, Casez O, Cabre P, Montcuquet A, Créange A, Camdessanché J, Bakchine S, Maurousset A, Hankiewicz K, Pottier C, Maubeuge N, Dimitri Boulos D, Nifle C, Vukusic S, Clavelou P. Untreated patients with multiple sclerosis: A study of French expert centers. European Journal of Neurology 2021;28(6):2026 View
  12. Khan R, Ross A, Willett K, Dine K, Banas R, Brown L, Shindler K. Amnion-Derived Multipotent Progenitor Cells Suppress Experimental Optic Neuritis and Myelitis. Neurotherapeutics 2021;18(1):448 View
  13. Bonafede M, Mehta R, Kim G, Sruti I, Tian M, Pelletier C, Goldfarb N. Productivity Loss and Associated Costs Among Employed Patients Receiving Disease-Modifying Treatment for Multiple Sclerosis. PharmacoEconomics - Open 2021;5(1):23 View
  14. Occhiogrosso R, Ren S, Tayob N, Li T, Gagnon H, Paz A, Freedman R. Feasibility of an Online Patient Community to Support Older Women With Newly Diagnosed Breast Cancer. Clinical Breast Cancer 2022;22(2):178 View
  15. Algahtani H, Almarri A, Alharbi J, Aljahdali M, Haimed R, Hariri R. Multiple Sclerosis in Saudi Arabia: Clinical, Social, and Psychological Aspects of the Disease. Cureus 2021 View
  16. Lacinova K, Thokala P, Nicholas R, Dobay P, Scalfaro E, Angehrn Z, Brennan R, Boer I, Lines C, Adlard N. ENTIMOS: A Discrete Event Simulation Model for Maximising Efficiency of Infusion Suites in Centres Treating Multiple Sclerosis Patients. Applied Health Economics and Health Policy 2022;20(5):731 View
  17. Seitaridou Y, Tsekov I, Kamusheva M, Dimitrova M, Petrova G. Analysis of patients’ access to reimbursed biotechnological medicines for multiple sclerosis in Bulgaria and Greece. Expert Review of Pharmacoeconomics & Outcomes Research 2022;22(2):241 View
  18. Das J, Rog D, Middleton R, Rodgers J, Fry R, Nicholas R. The association between deprivation and the access to disease modifying therapies for multiple sclerosis: An England wide community-based study in the UK MS Register. Multiple Sclerosis and Related Disorders 2022;57:103474 View
  19. Lotfi R, Chigr F, Najimi M. The impact of sociodemographic characteristics on diagnosis and access to disease-modifying treatment for patients with multiple sclerosis in Morocco. Multiple Sclerosis and Related Disorders 2022;67:104193 View
  20. Yeh E, Giovannoni G, Hawkes C, Lechner-Scott J, Levy M. High efficacy treatment is not enough in MS: Socioeconomic factors are key to improving outcomes. Multiple Sclerosis and Related Disorders 2022;61:103816 View
  21. Tedesco Triccas L, Maris A, Lamers I, Calcius J, Coninx K, Spooren A, Feys P. Do people with multiple sclerosis perceive upper limb improvements from robotic-mediated therapy? A mixed methods study. Multiple Sclerosis and Related Disorders 2022;68:104159 View
  22. Damavandi A, Mirmosayyeb O, Ebrahimi N, Zalpoor H, khalilian P, Yahiazadeh S, Eskandari N, Rahdar A, Kumar P, Pandey S. Advances in nanotechnology versus stem cell therapy for the theranostics of multiple sclerosis disease. Applied Nanoscience 2023;13(6):4043 View
  23. Zeineddine M, Al-Hajje A, Salameh P, Helme A, Thor M, Boumediene F, Yamout B. Barriers to accessing multiple sclerosis disease-modifying therapies in the Middle East and North Africa region: A regional survey-based study. Multiple Sclerosis and Related Disorders 2023;79:104959 View
  24. van Til J, Pearce A, Ozdemir S, Hollin I, Peay H, Wu A, Ostermann J, Deal K, Craig B. Role Preferences in Medical Decision Making: Relevance and Implications for Health Preference Research. The Patient - Patient-Centered Outcomes Research 2024;17(1):3 View
  25. Schauf M, Chinthapatla H, Dimri S, Li E, Hartung D. Economic burden of multiple sclerosis in the United States: A systematic literature review. Journal of Managed Care & Specialty Pharmacy 2023;29(12):1354 View
  26. Mallawaarachchi G, Rog D, Das J. Ethnic disparities in the epidemiological and clinical characteristics of multiple sclerosis. Multiple Sclerosis and Related Disorders 2024;81:105153 View
  27. Das J, Rog D, Middleton R, Rodgers J, Nicholas R. University education facilitates uptake of disease-modifying therapies for multiple sclerosis: A community-based study using the UK MS Register. Multiple Sclerosis Journal 2024;30(2):192 View
  28. Singer B, Feng J, Chiong-Rivero H. Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption. Journal of Neurology 2024;271(6):3116 View
  29. Mossburg S, Kilany M, Jinnett K, Nguyen C, Soles E, Wood-Palmer D, Aly M. A Rapid Review of Interventions to Improve Care for People Who Are Medically Underserved with Multiple Sclerosis, Diabetic Retinopathy, and Lung Cancer. International Journal of Environmental Research and Public Health 2024;21(5):529 View
  30. Das J, Mallawaarachchi G, Grimshaw J, Jackson T, Talbot P, Sharaf N, Kalatha T, Lord L, Pace A, Mihalova T, Heal C, Rog D. Ethnicity and deprivation negatively impact the access to disease-modifying therapy for relapsing-remitting multiple sclerosis: a retrospective, single-centre study. Journal of Neurology, Neurosurgery & Psychiatry 2024:jnnp-2024-333338 View
  31. Agarwal R, Risk B, Sandlin D, Mulamalla A, Sadigh G, Allen J, Fleischer C. Effects of financial toxicity and socioeconomic status on MRI follow‐up time in multiple sclerosis. Clinical Neuroimaging 2024;1(1-2) View